Subcutaneous unfractionated heparin vs low molecular weight heparin
All‐cause mortality (7 days ‐ 3 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in all‐cause mortality (7 days ‐ 3 months) compared with low molecular weight heparin (low certainty).
1 finding from 1 review
- Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism 2017 · Cochrane Headline outcomes onlyOR 0.73 [0.5, 1.07]7 studies · 2272 participantsLow